There exists a need to further identify and particularly characterize these cancer effectors and tumor suppressors, including PTEN, and alterations in PTEN expression and/or activity via post translational or other means that can ultimately be used in monitoring, evaluating, diagnosing, and therapeutic design strategies for the improved treatment and outcome in cancer.